Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The gut microbiome in patients with chronic lymphocytic leukemia

    Research output: Contribution to journalLetterResearchpeer-review

  2. Increments in DNA-thioguanine level during thiopurine enhanced maintenance therapy of acute lymphoblastic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Progression of the pluripotent epiblast depends upon the NMD Factor UPF2

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Engineering human mini-bones for the standardized modeling of healthy hematopoiesis, leukemia, and solid tumor metastasis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Deficiency of mature B cells does not alter the atherogenic response to castration in male mice

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

ASXL1 is one of the most commonly mutated genes in myeloid malignancies, including Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). In order to further our understanding of the role of ASXL1 lesions in malignant hematopoiesis, we generated a novel knock-in mouse model carrying the most frequent ASXL1 mutation identified in MDS patients, p.G643WfsX12. Mutant mice did not display any major hematopoietic defects nor developed any apparent hematological disease. In AML patients, ASXL1 mutations co-occur with mutations in CEBPA and we therefore generated compound Cebpa and Asxl1 mutated mice. Using a transplantation model, we found that the mutated Asxl1 allele significantly accelerated disease development in a CEBPA mutant context. Importantly, we demonstrated that, similar to the human setting, Asxl1 mutated mice responded poorly to chemotherapy. This model therefore constitutes an excellent experimental system for further studies into the clinically important question of chemotherapy resistance mediated by mutant ASXL1.

Original languageEnglish
JournalHaematologica
Volume106
Issue number4
Pages (from-to)1000-1007
Number of pages8
ISSN0390-6078
DOIs
Publication statusPublished - 1 Apr 2021

ID: 60067627